Home | Metabolism | Phenylketonuria (PKU) | Publications | Publication: Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers
Publication: Phase I clinical evaluation of CNSA-001 (sepiapterin), a novel pharmacological treatment for phenylketonuria and tetrahydrobiopterin deficiencies, in healthy volunteers
This research article inMolecular Genetics and Metabolism Reports, reports results from a Phase 1 clinical study of CNSA-001 (sepiapterin), an agent being investigated for potential treatment of BH4deficiencies and phenylketonuria (PKU)
Results from a randomized, double-blind, dose-ranging, Phase 1 clinical trial of 83 healthy subjects who were administered CNSA-001 or placebo are presented and discussed
The pharmacokinetic profile, including plasma levels of sepiapterin and BH4 following administration of CNSA-001 is reported here, along with adverse events associated with treatment
Smith N, Longo N, Levert K, et al.Mol Genet Metab Rep. 2019;126(4):406–412
Once registered, you will be provided the DOI and PubMed links for this publication.
Register now to unlock the content
Register now to access the content on this page
If not, register below
MED-ALL-PKU-2100026 | October 2021
Sign in or register to access exclusive content on this site
Some cookies are essential, others help us improve your experience by providing insights into how the website is used. Select one or more of the cookie types listed below, and then save your preferences. Refer to our Cookies Statement for more information.
Performance cookies, which help us measure the website’s performance and improve your experience. In using performance cookies we do not store any personal data, and only use the information collected through these cookies in aggregated and anonymised form.